Full TitleIIT2016-01-Tuli-DURVARAD: A Phase I/II Study of Durvalumab (Medi 4736) and Stereotactic Ablative Body Radiotherapy (SABR) Locally Advanced Pancreatic Adenocarcinoma (LAPC)
The purpose of this study is to find out if combining durvalumab immunotherapy with standard stereotactic ablative radiation therapy is a safe and effective treatment for people with locally advanced or borderline operable pancreatic cancer that has already been treated with up to six months of chemotherapy. Durvalumab is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have locally advanced or borderline inoperable pancreatic cancer and already had up to six months of FOLFIRINOX chemotherapy.
- Patients may not have previously received immunotherapy.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Eileen O’Reilly at 646-888-4182.